Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China
Lymphoid and myeloid neoplasms are common malignant tumors in China, which threaten people’s health. To improve the diagnosis and treatment of lymphoma, the National Health Commission of the People’s Republic of China revised Chinese guidelines for diagnosis and treatment of malignant lymphoma in 2018.
The new guidelines are based on the Classification of Tumours of Haematopoietic and Lymphoid Tissues revised by the World Health Organization in 2016. The new edition provided principles of accurate pathological diagnosis of lymphoma on the basis of various scales including histomorphology, immunohistochemistry, fluorescent immunohybridization and genetics. Moreover, new categories such as high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations were added in the revised edition.
PDF阅读
